How much revenue did argenx generate this year?
argenx has achieved a revenue of 2.06 B USD this year.
argenx Revenue 2024
argenx Revenue
2.06 B USD
Ticker
ARGX.BR
ISIN
NL0010832176
WKN
A11602
In 2024, argenx's sales reached 2.06 B USD, a 67.58% difference from the 1.23 B USD sales recorded in the previous year.
The argenx Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 6.47 | 17,14 |
| 2028e | 5.8 | 19,12 |
| 2027e | 4.93 | 22,51 |
| 2026e | 3.93 | 28,23 |
| 2025e | 2.93 | 37,86 |
| 2024e | 2.06 | 53,94 |
| 2023 | 1.23 | 90,39 |
| 2022 | 0.41 | 92,83 |
| 2021 | 0.5 | 222,91 |
| 2020 | 0.04 | 2687,68 |
| 2019 | 0.08 | 1412,76 |
| 2018 | 0.02 | 4732,69 |
| 2017 | 0.04 | 2791,92 |
| 2016 | 0.02 | 7161,62 |
| 2015 | 0.01 | 16172,76 |
| 2014 | 0 | 29512,27 |
| 2013 | 0 | 41361,23 |
| 2012 | 0 | 67180,67 |
| 2011 | 0 | 98095,66 |
argenx Revenue, EBIT, Net Income NL0010832176 · A11602
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into argenx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by argenx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects argenx’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of argenx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into argenx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing argenx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on argenx’s growth potential.
argenx Revenue, EBIT and net profit per share
| Date | argenx Revenue | argenx EBIT | argenx Net Income |
|---|---|---|---|
| 2029e | 6.47 B undefined | 3.11 B undefined | 1.99 B undefined |
| 2028e | 5.8 B undefined | 2.54 B undefined | 1.87 B undefined |
| 2027e | 4.93 B undefined | 1.91 B undefined | 1.4 B undefined |
| 2026e | 3.93 B undefined | 1.25 B undefined | 902.08 M undefined |
| 2025e | 2.93 B undefined | 534.04 M undefined | 389.8 M undefined |
| 2024e | 2.06 B undefined | -94.01 M undefined | -47.33 M undefined |
| 2023 | 1.23 B undefined | -420.64 M undefined | -295.05 M undefined |
| 2022 | 410.75 M undefined | -718.99 M undefined | -709.59 M undefined |
| 2021 | 497.28 M undefined | -348.75 M undefined | -408.27 M undefined |
| 2020 | 41.24 M undefined | -477.62 M undefined | -608.46 M undefined |
| 2019 | 78.46 M undefined | -198.89 M undefined | -181.21 M undefined |
| 2018 | 23.42 M undefined | -89.24 M undefined | -72.66 M undefined |
| 2017 | 39.7 M undefined | -25 M undefined | -30.61 M undefined |
| 2016 | 15.48 M undefined | -22.53 M undefined | -22.49 M undefined |
| 2015 | 6.85 M undefined | -15.61 M undefined | -15.31 M undefined |
| 2014 | 3.76 M undefined | -10.74 M undefined | -10.31 M undefined |
| 2013 | 2.68 M undefined | -6.23 M undefined | -6.13 M undefined |
| 2012 | 1.65 M undefined | -10.05 M undefined | -9.7 M undefined |
| 2011 | 1.13 M undefined | -3.64 M undefined | -3.47 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 1.13 M USD | -3.64 M USD | -3.47 M USD |
| 2012 | 1.65 M USD | -10.05 M USD | -9.7 M USD |
| 2013 | 2.68 M USD | -6.23 M USD | -6.13 M USD |
| 2014 | 3.76 M USD | -10.74 M USD | -10.31 M USD |
| 2015 | 6.85 M USD | -15.61 M USD | -15.31 M USD |
| 2016 | 15.48 M USD | -22.53 M USD | -22.49 M USD |
| 2017 | 39.7 M USD | -25 M USD | -30.61 M USD |
| 2018 | 23.42 M USD | -89.24 M USD | -72.66 M USD |
| 2019 | 78.46 M USD | -198.89 M USD | -181.21 M USD |
| 2020 | 41.24 M USD | -477.62 M USD | -608.46 M USD |
| 2021 | 497.28 M USD | -348.75 M USD | -408.27 M USD |
| 2022 | 410.75 M USD | -718.99 M USD | -709.59 M USD |
| 2023 | 1.23 B USD | -420.64 M USD | -295.05 M USD |
| 2024e | 2.06 B USD | -94.01 M USD | -47.33 M USD |
| 2025e | 2.93 B USD | 534.04 M USD | 389.8 M USD |
| 2026e | 3.93 B USD | 1.25 B USD | 902.08 M USD |
| 2027e | 4.93 B USD | 1.91 B USD | 1.4 B USD |
| 2028e | 5.8 B USD | 2.54 B USD | 1.87 B USD |
| 2029e | 6.47 B USD | 3.11 B USD | 1.99 B USD |
argenx stock margins NL0010832176 · A11602
The argenx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of argenx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for argenx.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the argenx's sales revenue. A higher gross margin percentage indicates that the argenx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the argenx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the argenx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the argenx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the argenx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the argenx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
argenx Margin History
| argenx Gross margin | argenx Profit margin | argenx EBIT margin | argenx Profit margin |
|---|---|---|---|
| 2029e | 90.39 % | 48.07 % | 30.83 % |
| 2028e | 90.39 % | 43.82 % | 32.26 % |
| 2027e | 90.39 % | 38.84 % | 28.36 % |
| 2026e | 90.39 % | 31.74 % | 22.98 % |
| 2025e | 90.39 % | 18.24 % | 13.31 % |
| 2024e | 90.39 % | -4.57 % | -2.3 % |
| 2023 | 90.39 % | -34.3 % | -24.06 % |
| 2022 | 92.83 % | -175.04 % | -172.76 % |
| 2021 | 90.39 % | -70.13 % | -82.1 % |
| 2020 | 90.39 % | -1,158.06 % | -1,475.29 % |
| 2019 | 90.39 % | -253.49 % | -230.95 % |
| 2018 | 90.39 % | -381.01 % | -310.22 % |
| 2017 | 90.39 % | -62.97 % | -77.1 % |
| 2016 | 90.39 % | -145.56 % | -145.27 % |
| 2015 | 90.39 % | -227.68 % | -223.4 % |
| 2014 | 90.39 % | -286.02 % | -274.6 % |
| 2013 | 90.39 % | -232.46 % | -228.73 % |
| 2012 | 90.39 % | -609.09 % | -587.88 % |
| 2011 | 90.39 % | -322.12 % | -307.08 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 90.39 % | -322.12 % | -307.08 % |
| 2012 | 90.39 % | -609.09 % | -587.88 % |
| 2013 | 90.39 % | -232.46 % | -228.73 % |
| 2014 | 90.39 % | -286.02 % | -274.6 % |
| 2015 | 90.39 % | -227.68 % | -223.4 % |
| 2016 | 90.39 % | -145.56 % | -145.27 % |
| 2017 | 90.39 % | -62.97 % | -77.1 % |
| 2018 | 90.39 % | -381.01 % | -310.22 % |
| 2019 | 90.39 % | -253.49 % | -230.95 % |
| 2020 | 90.39 % | -1,158.06 % | -1,475.29 % |
| 2021 | 90.39 % | -70.13 % | -82.1 % |
| 2022 | 92.83 % | -175.04 % | -172.76 % |
| 2023 | 90.39 % | -34.3 % | -24.06 % |
| 2024e | 90.39 % | -4.57 % | -2.3 % |
| 2025e | 90.39 % | 18.24 % | 13.31 % |
| 2026e | 90.39 % | 31.74 % | 22.98 % |
| 2027e | 90.39 % | 38.84 % | 28.36 % |
| 2028e | 90.39 % | 43.82 % | 32.26 % |
| 2029e | 90.39 % | 48.07 % | 30.83 % |
argenx Aktienanalyse
What does argenx do?
Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding argenx's Sales Figures
The sales figures of argenx originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing argenx’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize argenx's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in argenx’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about argenx stock
How much was the turnover of the company argenx compared to the previous year?
The revenue of argenx has increased by 67.58% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of argenx?
The revenue of argenx is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of argenx measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of argenx so important for investors?
The revenue of argenx is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does argenx pay?
Over the past 12 months, argenx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, argenx is expected to pay a dividend of 0 USD.
What is the dividend yield of argenx?
The current dividend yield of argenx is .
When does argenx pay dividends?
argenx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of argenx?
argenx paid dividends every year for the past 0 years.
What is the dividend of argenx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is argenx located?
argenx is assigned to the 'Health' sector.
Wann musste ich die Aktien von argenx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of argenx from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did argenx pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of argenx in the year 2023?
In the year 2023, argenx distributed 0 USD as dividends.
In which currency does argenx pay out the dividend?
The dividends of argenx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The argenx stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von argenx
Our stock analysis for argenx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of argenx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
